SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-042954
Filing Date
2023-11-28
Accepted
2023-11-28 17:21:13
Documents
14
Period of Report
2023-11-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 58545
2 ex10-1.htm EX-10.1 161938
  Complete submission text file 0001493152-23-042954.txt   472772

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lixt-20231127.xsd EX-101.SCH 3785
4 XBRL DEFINITION FILE lixt-20231127_def.xml EX-101.DEF 26651
5 XBRL LABEL FILE lixt-20231127_lab.xml EX-101.LAB 36785
6 XBRL PRESENTATION FILE lixt-20231127_pre.xml EX-101.PRE 25275
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5306
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 231447608
SIC: 2834 Pharmaceutical Preparations